Under the agreement, Pathway Genomics will allow Medcan’s patients to use its Personal Genome Test.

Using only a saliva sample, the genetic test service reports a patient’s response to various drugs and prescription medications, as well as a patient’s propensity to develop certain diseases such as heart disease, type 2 diabetes and cancer.

Medcan medical director James Aw said knowledge of personal genomic information can provide a strong basis for an effective, preventive healthcare strategy for the clients.

"Pathway’s clinical test is leading-edge and we are pleased to partner with them on this initiative," Aw added.

Pathway Genomics CEO Jim Plante said, "Pathway’s extensive offering of genetic testing services enhances Medcan’s genetics program, and allows the clinic to offer highly personalized and clinically actionable genetic information to its patients."